Abstract
Helicobacter pylori (H. pylori) is a gram negative, spiral, microaerophylic bacterium that infects the stomach of more than 50% of the human population worldwide. H. pylori is well recognized as a critical factor in the majority of patients with peptic ulcer disease and successful treatment results in cure of the disease. On the other hand, H. pylori infection has been associated with several extra-intestinal diseases such as hepatic encephalopathy. In this study, a triple treatment was used in management and eradication of H. pylori infection. We hypothesized that H. pylori infection and/or eradication treatment increased the releasing of α-glutathione S-transferase (α-GST). We also investigated whether α-GST is a more sensitive marker than aminotransferases (traditional liver function tests) for hepatocellular damage. However, we did not find any association between both H. pylori infection and eradication treatment and α-GST levels. According to our data, eradication treatment did not cause hepatocellular damage.
Keywords: Alkaline Phosphatase (AP), Chronic Liver Disease, Helicobacter pylori, Glutathione S-transferase immunoassay, Liver Function Tests
Current Drug Safety
Title: Release of α-Glutathione s-Transferase (α-GST) and Hepatocellular Damage Induced by Helicobacter pylori and Eradication Treatment
Volume: 2 Issue: 1
Author(s): Bensu Karahalil, Seyhan Yagar and Yasemin Ozin
Affiliation:
Keywords: Alkaline Phosphatase (AP), Chronic Liver Disease, Helicobacter pylori, Glutathione S-transferase immunoassay, Liver Function Tests
Abstract: Helicobacter pylori (H. pylori) is a gram negative, spiral, microaerophylic bacterium that infects the stomach of more than 50% of the human population worldwide. H. pylori is well recognized as a critical factor in the majority of patients with peptic ulcer disease and successful treatment results in cure of the disease. On the other hand, H. pylori infection has been associated with several extra-intestinal diseases such as hepatic encephalopathy. In this study, a triple treatment was used in management and eradication of H. pylori infection. We hypothesized that H. pylori infection and/or eradication treatment increased the releasing of α-glutathione S-transferase (α-GST). We also investigated whether α-GST is a more sensitive marker than aminotransferases (traditional liver function tests) for hepatocellular damage. However, we did not find any association between both H. pylori infection and eradication treatment and α-GST levels. According to our data, eradication treatment did not cause hepatocellular damage.
Export Options
About this article
Cite this article as:
Karahalil Bensu, Yagar Seyhan and Ozin Yasemin, Release of α-Glutathione s-Transferase (α-GST) and Hepatocellular Damage Induced by Helicobacter pylori and Eradication Treatment, Current Drug Safety 2007; 2 (1) . https://dx.doi.org/10.2174/157488607779315426
DOI https://dx.doi.org/10.2174/157488607779315426 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MicroRNA-183 Functions As an Oncogene by Regulating PDCD4 in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Anticancer Potential and Molecular Targets of Pristimerin: A Mini- Review
Current Cancer Drug Targets The PI3 Kinase Signaling Pathway in Prostate Cancer
Current Cancer Drug Targets Nonviral Gene Therapy
Current Gene Therapy Comparison of Ultrasonography and Computed Tomography Features of Calcified Thyroid Nodules
Current Medical Imaging Retinoids in Cancer Chemoprevention
Current Cancer Drug Targets Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Current Cancer Drug Targets Role of Early Growth Response-1 in the Development of Alcohol-Induced Steatosis
Current Molecular Pharmacology The Crosstalk between Tissue Engineering and Pharmaceutical Biotechnology: Recent Advances and Future Directions
Current Pharmaceutical Biotechnology Genetic Variation in SLCO2B1 is Associated with Serum Levels of Testosterone and its Metabolites Prior to and Two Days after Testosterone Administration
Current Pharmacogenomics and Personalized Medicine New Approaches to Target the Androgen Receptor and STAT3 for Prostate Cancer Treatments
Mini-Reviews in Medicinal Chemistry Can we Target the Chemokine Network for Cancer Therapeutics?
Current Cancer Drug Targets Peptides to Target Tumor Vasculature and Lymphatics for Improved Anti-Angiogenesis Therapy
Current Cancer Drug Targets Natural Products in Structure-Assisted Design of Molecular Cancer Therapeutics
Current Pharmaceutical Design Parental Tobacco Control in the Child Healthcare Setting
Current Pediatric Reviews Interactions between Ketamine and Magnesium for the Treatment of Pain: Current State of the Art
CNS & Neurological Disorders - Drug Targets Ion Transporters in Brain Tumors
Current Medicinal Chemistry Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Genetics of the First Seven Proprotein Convertase Enzymes in Health and Disease
Current Genomics Evolution and Pathogenesis of Oncoviruses Associated with Head and Neck Cancer: History and Current Concepts
Recent Patents on Biomarkers